Ophthalmic drug delivery device

• US 20030003129A1
• Filed: 07/01/2002
• Published: 01/02/2003
• Est. Priority Date: 10/21/1999
• Status: Active Grant

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Incorporated
• Inventors: Yaacobi, Yoseph
• Granted Patent: US 6,669,950 B2
• Time in Patent Office: Days
• US Class Current: 424/428
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61F 9/00781 Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment drainage implants in general A61M27/002
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

The present invention is directed to a drug delivery device for a human eye. The human eye has a sclera, an inferior oblique muscle, and a macula. The device of the present invention includes a pharmaceutically active agent, and a geometry that facilitates the implantation of the device on an outer surface of the sclera, beneath the inferior oblique muscle, and with the pharmaceutically active agent disposed above the macula. Methods of delivery a pharmaceutically active agent to the posterior segment of the human eye are also disclosed.

Claims

1. A drug delivery device for a human eye, said eye having a sclera, an inferior oblique muscle, and a macula, said device comprising:

a pharmaceutically active agent; and

a geometry that facilitates an implantation of said device on an outer surface of said sclera, beneath said inferior oblique muscle, and with said pharmaceutically active agent disposed above said macula.